Germantown, Maryland, and Venlo, the Netherlands, June 27, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it welcomes new guidelines in the United States that recommend screening at-risk children of all ages for latent tuberculosis (TB) infection with modern blood-based tests such as QIAGEN’s market-leading QuantiFERON-TB Gold Plus (QFT-Plus). The new guidelines from the American Academy of Pediatrics (AAP) emphasize testing for TB with modern interferon-ga ...